Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remifentanil + remimazolam (Yonsei University)
- Development stage
- Phase 4
- Lead developer
- Yonsei University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
remifentanil + remimazolam is an investigational anesthesia combination regimen being evaluated by Yonsei University for total intravenous anesthesia (TIVA). This regimen combines remifentanil, an ultra-short-acting mu-opioid receptor agonist that provides potent analgesia, with remimazolam, a short-acting benzodiazepine that acts as a GABA-A receptor positive allosteric modulator to induce sedation. The combination is specifically being studied in the context of laparoscopic-assisted gastrectomy for patients with stomach neoplasms (gastric cancer) to assess its impact on postoperative pain and recovery compared to other opioid-sedative combinations like sufentanil-remimazolam.
- Other names
- remifentanil-remimazolamremifentanil-remimazolam TIVA
02
Targets
BZD site (GABA-A receptor benzodiazepine site)MOR (Mu opioid receptor)GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on remifentanil + remimazolam (Yonsei University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remifentanil + remimazolam (Yonsei University).